Literature DB >> 21361279

Synthesis, characterization, and cytotoxicity of platinum(IV) carbamate complexes.

Justin J Wilson1, Stephen J Lippard.   

Abstract

The synthesis, characterization, and cytotoxicity of eight new platinum(IV) complexes having the general formula cis,cis,trans-[Pt(NH(3))(2)Cl(2)(O(2)CNHR)(2)] are reported, where R = tert-butyl (4), cyclopentyl (5), cyclohexyl (6), phenyl (7), p-tolyl (8), p-anisole (9), 4-fluorophenyl (10), or 1-naphthyl (11). These compounds were synthesized by reacting organic isocyanates with the platinum(IV) complex cis,cis,trans-[Pt(NH(3))(2)Cl(2)(OH)(2)]. The electrochemistry of the compounds was investigated by cyclic voltammetry. The aryl carbamate complexes 7-11 exhibit reduction peak potentials near -720 mV vs Ag/AgCl, whereas the alkyl carbamate complexes display reduction peak potentials between -820 and -850 mV vs Ag/AgCl. The cyclic voltammograms of cis,cis,trans-[Pt(NH(3))(2)Cl(2)(O(2)CCH(3))(2)] (1), cis,cis,trans-[Pt(NH(3))(2)Cl(2)(O(2)CCF(3))(2)] (2), and cis-[Pt(NH(3))(2)Cl(4)] (3) were measured for comparison. Density functional theory studies were undertaken to investigate the electronic structures of 1-11 and to determine their adiabatic electron affinities. A linear correlation (R(2) = 0.887) between computed adiabatic electron affinities and measured reduction peak potentials was discovered. The biological activity of 4-11 and, for comparison, cisplatin was evaluated in human lung cancer A549 and normal MRC-5 cells by the MTT assay. The compounds exhibit comparable or slightly better activity than cisplatin against the A549 cells. In MRC-5 cells, all are equally or slightly less cytotoxic than cisplatin, except for 4 and 5, which are more toxic.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21361279      PMCID: PMC3065953          DOI: 10.1021/ic2000816

Source DB:  PubMed          Journal:  Inorg Chem        ISSN: 0020-1669            Impact factor:   5.165


  46 in total

Review 1.  195Pt NMR--theory and application.

Authors:  Brett M Still; P G Anil Kumar; Janice R Aldrich-Wright; William S Price
Journal:  Chem Soc Rev       Date:  2006-11-17       Impact factor: 54.564

2.  Slowing of cisplatin aquation in the presence of DNA but not in the presence of phosphate: improved understanding of sequence selectivity and the roles of monoaquated and diaquated species in the binding of cisplatin to DNA.

Authors:  M S Davies; S J Berners-Price; T W Hambley
Journal:  Inorg Chem       Date:  2000-12-11       Impact factor: 5.165

3.  New reduction pathways for ctc-[PtCl2(CH3CO2)2(NH3)(Am)] anticancer prodrugs.

Authors:  Alina Nemirovski; Inbal Vinograd; Khuloud Takrouri; Ana Mijovilovich; Annette Rompel; Dan Gibson
Journal:  Chem Commun (Camb)       Date:  2010-02-12       Impact factor: 6.222

4.  Mitaplatin, a potent fusion of cisplatin and the orphan drug dichloroacetate.

Authors:  Shanta Dhar; Stephen J Lippard
Journal:  Proc Natl Acad Sci U S A       Date:  2009-12-10       Impact factor: 11.205

5.  Polyvalent oligonucleotide gold nanoparticle conjugates as delivery vehicles for platinum(IV) warheads.

Authors:  Shanta Dhar; Weston L Daniel; David A Giljohann; Chad A Mirkin; Stephen J Lippard
Journal:  J Am Chem Soc       Date:  2009-10-21       Impact factor: 15.419

6.  Nanoscale coordination polymers for platinum-based anticancer drug delivery.

Authors:  William J Rieter; Kimberly M Pott; Kathryn M L Taylor; Wenbin Lin
Journal:  J Am Chem Soc       Date:  2008-08-08       Impact factor: 15.419

Review 7.  The resurgence of platinum-based cancer chemotherapy.

Authors:  Lloyd Kelland
Journal:  Nat Rev Cancer       Date:  2007-07-12       Impact factor: 60.716

8.  Postsynthetic modifications of iron-carboxylate nanoscale metal-organic frameworks for imaging and drug delivery.

Authors:  Kathryn M L Taylor-Pashow; Joseph Della Rocca; Zhigang Xie; Sylvie Tran; Wenbin Lin
Journal:  J Am Chem Soc       Date:  2009-10-14       Impact factor: 15.419

9.  Novel cis- and trans-configured bis(oxime)platinum(II) complexes: synthesis, characterization, and cytotoxic activity.

Authors:  Yulia Yu Scaffidi-Domianello; Kristof Meelich; Michael A Jakupec; Vladimir B Arion; Vadim Yu Kukushkin; Mathea Sophia Galanski; Bernhard K Keppler
Journal:  Inorg Chem       Date:  2010-06-21       Impact factor: 5.165

10.  Novel di- and tetracarboxylatoplatinum(IV) complexes. Synthesis, characterization, cytotoxic activity, and DNA platination.

Authors:  Michael R Reithofer; Seied M Valiahdi; Michael A Jakupec; Vladimir B Arion; Alexander Egger; Mathea Sophia Galanski; Bernhard K Keppler
Journal:  J Med Chem       Date:  2007-11-22       Impact factor: 7.446

View more
  20 in total

1.  Oxidative halogenation of cisplatin and carboplatin: synthesis, spectroscopy, and crystal and molecular structures of Pt(IV) prodrugs.

Authors:  Timothy C Johnstone; Sarah M Alexander; Justin J Wilson; Stephen J Lippard
Journal:  Dalton Trans       Date:  2015-01-07       Impact factor: 4.390

Review 2.  Synthetic methods for the preparation of platinum anticancer complexes.

Authors:  Justin J Wilson; Stephen J Lippard
Journal:  Chem Rev       Date:  2013-11-27       Impact factor: 60.622

3.  Diamminetetrakis(carboxylato)platinum(IV) complexes--synthesis, characterization, and cytotoxicity.

Authors:  Björn R Hoffmeister; Mahsa S Adib-Razavi; Michael A Jakupec; Markus Galanski; Bernhard K Keppler
Journal:  Chem Biodivers       Date:  2012-09       Impact factor: 2.408

4.  Conjugation of cisplatin analogues and cyclooxygenase inhibitors to overcome cisplatin resistance.

Authors:  Wilma Neumann; Brenda C Crews; Menyhárt B Sárosi; Cristina M Daniel; Kebreab Ghebreselasie; Matthias S Scholz; Lawrence J Marnett; Evamarie Hey-Hawkins
Journal:  ChemMedChem       Date:  2014-10-15       Impact factor: 3.466

5.  Synthesis and characterization of Pt(IV) fluorescein conjugates to investigate Pt(IV) intracellular transformations.

Authors:  Ying Song; Kogularamanan Suntharalingam; Jessica S Yeung; Maksim Royzen; Stephen J Lippard
Journal:  Bioconjug Chem       Date:  2013-09-10       Impact factor: 4.774

Review 6.  The Next Generation of Platinum Drugs: Targeted Pt(II) Agents, Nanoparticle Delivery, and Pt(IV) Prodrugs.

Authors:  Timothy C Johnstone; Kogularamanan Suntharalingam; Stephen J Lippard
Journal:  Chem Rev       Date:  2016-02-11       Impact factor: 60.622

7.  Conjugates of cisplatin and cyclooxygenase inhibitors as potent antitumor agents overcoming cisplatin resistance.

Authors:  Wilma Neumann; Brenda C Crews; Lawrence J Marnett; Evamarie Hey-Hawkins
Journal:  ChemMedChem       Date:  2014-05-06       Impact factor: 3.466

Review 8.  Nanoscale drug delivery platforms overcome platinum-based resistance in cancer cells due to abnormal membrane protein trafficking.

Authors:  Xue Xue; Matthew D Hall; Qiang Zhang; Paul C Wang; Michael M Gottesman; Xing-Jie Liang
Journal:  ACS Nano       Date:  2013-12-10       Impact factor: 15.881

9.  Using an RNAi Signature Assay To Guide the Design of Three-Drug-Conjugated Nanoparticles with Validated Mechanisms, In Vivo Efficacy, and Low Toxicity.

Authors:  Jonathan C Barnes; Peter M Bruno; Hung V-T Nguyen; Longyan Liao; Jenny Liu; Michael T Hemann; Jeremiah A Johnson
Journal:  J Am Chem Soc       Date:  2016-09-14       Impact factor: 15.419

10.  Modulation of Ligand Fluorescence by the Pt(II)/Pt(IV) Redox Couple.

Authors:  Justin J Wilson; Stephen J Lippard
Journal:  Inorganica Chim Acta       Date:  2012-01-03       Impact factor: 2.545

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.